EGFR

Researchers find novel mechanism of resistance to anti-cancer drugs

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.

New tools to combat kidney fibrosis

Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.

Glowing receptors help find and track cancerous growth

Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.

New target for colorectal cancer

Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.

firefighters battle a wildfire

EGF receptor found to regulate macrophage inflammation in gut

Researchers at Vanderbilt University School of Medicine have uncovered a link between epidermal growth factor receptor (EGFR) signaling and the inflammatory response to bacterial infection in the gastrointestinal tract.

Drug combos for glioblastoma

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

1 2